Weekly Trademark Review Oct. 22, 2013
This article was originally published in The Tan Sheet
OTC drug, personal care product and nutriotional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.
You may also be interested in...
Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.
Patent litigation settlements have paved the way for Endo’s Par and Teva to secure the first US approvals for generic versions of Novartis’ Afinitor everolimus brand.
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.